Agonistic mAb targeting co-stimulatory molecules of the tumour necrosis factor receptor superfamily (TNFRSF) (e.g. OX40, CD40, 4-1BB, GITR or CD27) are attractive candidates for cancer immunotherapy. This evidence concerns the gene CD27 and cancer.